The OASIS 1 trial by Filip K Knop and colleagues1 demonstrates the greatest magnitude of
weight loss to date among oral anti-obesity medications. 2− 4 In this randomised, double …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

The landscape of pharmacological interventions in combating obesity has long struggled
with the formidable challenge of balancing efficacy and safety, with weightloss drugs often …

Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …

Diabetes remains a pressing global health concern, affecting approximately 540 million
people worldwide. 1 As prevalence continues to rise, diabetes places substantial burdens …

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

We read, with great interest, the Article by Patrick O'Neil and colleagues1 on the efficacy and
safety of semaglutide for weight loss combined with lifestyle intervention. The authors should …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2· 4 mg versus semaglutide 1· 0 mg (the dose approved for …